辅助化疗和放疗在非小细胞肺癌（NSCLC）治疗中的应用
Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC).
作者信息
Zaric Bojan, Stojsic Vladimir, Tepavac Aleksandar, Sarcev Tatjana, Zarogoulidis Paul, Darwiche Kaid, Tsakiridis Kosmas, Karapantzos Ilias, Kesisis Georgios, Kougioumtzi Ioanna, Katsikogiannis Nikolaos, Machairiotis Nikolaos, Stylianaki Aikaterini, Foroulis Christophoros N, Zarogoulidis Konstantinos, Perin Branislav
机构信息
Institute for Pulmonary Diseases of Vojvodina, Clinic for Thoracic Oncology, Faculty of Medicine, University of Novi Sad, Serbia;
出版信息
J Thorac Dis. 2013 Sep;5 Suppl 4(Suppl 4):S371-7. doi: 10.3978/j.issn.2072-1439.2013.05.16.
Abstract
Lung cancer is one of the most common human malignancies and remains the leading cause of cancer related deaths worldwide. Many recent technological advances led to improved diagnostics and staging of lung cancer. With development of new treatment options such as targeted therapies there might be improvement in progression free survival of patients with advanced stage non-small cell lung cancer (NSCLC). Improvement in overall survival is still reserved for selected patients and selected treatments. One of the mostly investigated therapeutic options is adjuvant treatment. There are many open issues in selection of patients and administration of appropriate adjuvant treatment.
摘要
肺癌是人类最常见的恶性肿瘤之一，仍是全球癌症相关死亡的主要原因。最近的许多技术进步使肺癌的诊断和分期得到了改善。随着靶向治疗等新治疗方案的发展，晚期非小细胞肺癌（NSCLC）患者的无进展生存期可能会有所改善。总体生存率的提高仍仅限于部分患者和特定治疗。辅助治疗是研究最多的治疗选择之一。在患者选择和适当辅助治疗的实施方面存在许多未解决的问题。
相似文献
1
Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC).
J Thorac Dis. 2013 Sep;5 Suppl 4(Suppl 4):S371-7. doi: 10.3978/j.issn.2072-1439.2013.05.16.
2
Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Cancer Prev Control. 1997 Dec;1(5):366-78.
3
Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Chest. 2013 May;143(5 Suppl):e278S-e313S. doi: 10.1378/chest.12-2359.
4
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
5
Treatment of advanced (stages III and IV) non-small-cell lung cancer.
Curr Probl Cancer. 1998 Mar-Apr;22(2):85-132. doi: 10.1016/s0147-0272(98)90010-1.
6
Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.
Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5022s-5026s. doi: 10.1158/1078-0432.CCR-05-9001.
7
The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.
Ann Thorac Cardiovasc Surg. 2007 Apr;13(2):73-7.
8
Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC).
Lung Cancer. 2002 Jul;37(1):65-71. doi: 10.1016/s0169-5002(02)00026-0.
9
Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung Cancer undergoing surgery: a propensity-matched analysis.
BMC Cancer. 2018 Nov 6;18(1):1067. doi: 10.1186/s12885-018-4900-x.
10
Developments in the treatment of non-small cell lung cancer.
Anticancer Res. 2007 Jul-Aug;27(4C):2823-7.
引用本文的文献
1
Significance of metastatic lymph nodes ratio in overall survival for patients with resected nonsmall cell lung cancer: a retrospective cohort study.
Eur J Cancer Prev. 2024 Jul 1;33(4):376-385. doi: 10.1097/CEJ.0000000000000868. Epub 2024 May 16.
2
Nebulisation of Paclitaxel, Sotatercept and Iloprost for pulmonary hypertension for lung cancer. From to .
J Cancer. 2024 Jan 1;15(4):871-879. doi: 10.7150/jca.90732. eCollection 2024.
3
Examination of Combined Treatment of Ginsenoside Rg3 and 5-Fluorouracil in Lung Adenocarcinoma Cells.
Comput Math Methods Med. 2022 Jun 28;2022:2813142. doi: 10.1155/2022/2813142. eCollection 2022.
4
SNRPB is a mediator for cellular response to cisplatin in non-small-cell lung cancer.
Med Oncol. 2021 Apr 9;38(5):57. doi: 10.1007/s12032-021-01502-0.
5
Genetic variants of and in the NLRP3 inflammasome pathway are associated with non-small cell lung cancer survival.
Am J Cancer Res. 2020 Aug 1;10(8):2582-2595. eCollection 2020.
6
Yifei Tongluo, a Chinese Herbal Formula, Suppresses Tumor Growth and Metastasis and Exerts Immunomodulatory Effect in Lewis Lung Carcinoma Mice.
Molecules. 2019 Feb 18;24(4):731. doi: 10.3390/molecules24040731.
7
Dehydrocostus Lactone Enhances Chemotherapeutic Potential of Doxorubicin in Lung Cancer by Inducing Cell Death and Limiting Metastasis.
Med Sci Monit. 2018 Nov 2;24:7850-7861. doi: 10.12659/MSM.911410.
8
Apoptosis of Lewis Lung Carcinoma Cells Induced by Microwave via p53 and Proapoptotic Proteins .
Chin Med J (Engl). 2017;130(1):15-22. doi: 10.4103/0366-6999.196587.
9
Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature.
J Cancer. 2016 Jan 13;7(4):377-90. doi: 10.7150/jca.13611. eCollection 2016.
10
Inhibitory effect of traditional oriental medicine-derived monoamine oxidase B inhibitor on radioresistance of non-small cell lung cancer.
Sci Rep. 2016 Feb 24;6:21986. doi: 10.1038/srep21986.
本文引用的文献
1
Postoperative radiation therapy for non-small cell lung cancer and thymic malignancies.
Cancers (Basel). 2012 Mar 14;4(1):307-22. doi: 10.3390/cancers4010307.
2
Improving referral of patients for consideration of adjuvant chemotherapy after surgical resection of lung cancer.
Curr Oncol. 2012 Dec;19(6):e422-7. doi: 10.3747/co.19.1133.
3
Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research.
J Exp Clin Cancer Res. 2011 Dec 29;30(1):115. doi: 10.1186/1756-9966-30-115.
4
Clinical implications of the margin cytology findings and margin/tumor size ratio in patients who underwent pulmonary excision for peripheral non-small cell lung cancer.
Surg Today. 2012 Feb;42(3):238-44. doi: 10.1007/s00595-011-0031-6. Epub 2011 Nov 10.
5
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.
Ann Oncol. 2012 Jan;23(1):86-93. doi: 10.1093/annonc/mdr033. Epub 2011 Apr 6.
6
Bronchial resection margin length and clinical outcome in non-small cell lung cancer.
Eur J Cardiothorac Surg. 2011 Nov;40(5):1151-6. doi: 10.1016/j.ejcts.2011.02.042. Epub 2011 Mar 30.
7
Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data.
Oncologist. 2011;16(5):672-81. doi: 10.1634/theoncologist.2010-0150. Epub 2011 Mar 4.
8
Current status of postoperative radiation for non-small-cell lung cancer.
Semin Radiat Oncol. 2010 Jul;20(3):192-200. doi: 10.1016/j.semradonc.2010.01.008.
9
Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2010 May;21 Suppl 5:v103-15. doi: 10.1093/annonc/mdq207.
10
Radiation dose-volume effects in the heart.
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S77-85. doi: 10.1016/j.ijrobp.2009.04.093.
Zotero 插件